MacroGenics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MacroGenics, Inc. (NASDAQ: MGNX) is a clinical-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative monoclonal antibody-based therapeutics for cancer treatment; its proprietary platforms include DART molecules, antibody-drug conjugates (ADCs), and Fc-optimized monoclonal antibodies (mAbs). The company, founded in 2000 and headquartered in Rockville, Maryland, focuses on oncology indications such as metastatic castration-resistant prostate cancer (mCRPC), prostate cancer (PROC), colorectal cancer with gynecologic origins (CCGC), and multiple solid tumors, with operations primarily in the United States and partnerships extending globally. Core wholly-owned pipeline candidates comprise lorigerlimab (PD-1 x CTLA-4 DART) in Phase 3 for mCRPC (LORIKEET study) and Phase 2 for PROC/CCGC (LINNET study); MGC026 (B7-H3 ADC), MGC028 (ADAM9 ADC), and MGC030 (undisclosed ADC), all in Phase 1 for solid tumors; partnered programs include MARGENZA (HER2 Fc-optimized mAb, global rights sold to TerSera Therapeutics LLC for $40 million upfront plus up to $35 million milestones), ZYNYZ (PD-1 mAb partnered with Incyte, supplemental BLA anticipated 2H2025 for squamous cell anal carcinoma), TZIELD (CD3 mAb partnered with Sanofi, regulatory decisions expected 2H2025 for type 1 diabetes), MGD024 (CD123 x CD3 DART under Gilead option, up to $1.7 billion potential), and undisclosed DART/TRIDENT bispecifics. Recent developments include a $70 million upfront royalty purchase agreement with Sagard Healthcare Partners for ZYNYZ in Q2 2025, appointment of Eric Risser as President and CEO outlining 2025-2026 priorities for pipeline advancement and capital efficiency, sale of MARGENZA rights to TerSera with an $8 million amendment fee to the prior partner in 4Q2024 and ongoing drug substance manufacturing, IND submission for MGC028 by end-2024 with Phase 1 initiation in 2025, and cash position of $176.5 million as of June 30, 2025, extending into H1 2027.
Company News
Bank of America Corp DE Buys 564,094 Shares of MacroGenics, Inc. $MGNX
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Rating of “Hold” by Brokerages
MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important
MacroGenics Provides Clinical Update on Ongoing Phase 1 Study for MGC026
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
MacroGenics (MGNX) Reports Q1 Loss, Tops Revenue Estimates
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
Will MacroGenics (MGNX) Report Negative Q1 Earnings? What You Should Know
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study